The center has called for mass vaccination across the country to prevent covid (Corona Virus) infection. But India is embroiled in a nationwide controversy over Bharat Biotech's covaccin. The effectiveness of covaccin has been questioned. This is because the ticker was allowed to be used before the end of the three-point trial. This time the results of the third round of trial are public. It became clear, how effective is this vaccine against corona infection? It is known how effective this vaccine is in preventing the terrible Delta variant.
What is the result of the third trial of the ticker?
Covaccin is about 7.8 percent effective in preventing coronary infections.
Vaccine manufacturer Bharat Biotech claims that covaccin is 75.2 percent effective against the Delta variant.
This vaccine is able to fight the SARS Cove-2 virus. Apart from delta, covaccin is also effective on B.1.617.1 (CAPA), B.1.1.7 (alpha), B.1.351 (beta), P2- B.1.1.28 (gamma) variants.
Bharat Biotech has claimed that the trial of covaccin is the biggest trial in the country. The trial was conducted on 25,798 people aged 18-96.
The vaccine has a lower rate of side effects than other vaccines, according to the manufacturer. The most common side effects, such as mild fever or headache, were reported in 12 percent of vaccine recipients. In addition, 0.5 percent of vaccine recipients had serious side effects.
Two weeks after the second dose, only 130 out of 18,963 people developed corona symptoms.
Covaccin has already been cleared for emergency use in 12 countries, including Brazil, the Philippines, Iran and Mexico.
Bharat Biotech has applied to the World Health Organization for clearance of covaccin for emergency use around the world.
